Table 1.
Patient characteristics of CLL cohorts.
| Parameters | AGMT-REVLIRIT cohort [18] | CLL validation cohort [20] |
|---|---|---|
| Total number (%) | 45 (100) | 98 (100) |
| Sex | ||
| Male (%) | 25 (56) | 68 (69) |
| Female (%) | 20 (44) | 30 (31) |
| Age (years) | ||
| Mean | 65.8 | 66.7 |
| Range | 43–80 | 38–89 |
| Duration of disease (years) | ||
| Mean | 3.8 | 5.4 |
| Range | 0–10.3 | 0–21.9 |
| RAI stage at diagnosis | ||
| nda | 2 (4) | |
| I | 7 (16) | |
| II | 16 (36) | |
| III | 12 (27) | |
| IV | 8 (18) | |
| Binet stage at diagnosis | ||
| nda | 2 (2) | |
| A | 91 (93) | |
| B | 4 (4) | |
| C | 1 (1) | |
| Molecular risk parameters | ||
| Unmutated Ig VH | 21 (47) | 43 (44) |
| IGHV nda | 5 (11) | 2 (2) |
| FISH karyotype | ||
| del11q | 9 (20) | 14 (14.3) |
| del13q | 29 (64) | 51 (52.0) |
| del17p | 4 (9) | 4 (4) |
| trisomy 12 | 6 (13) | 14 (14) |
| normal karyotype | 5 (11) | 23 (23) |
| karyotype nda | 1 (2) | 2 (2) |
| Treatment status | ||
| Untreated at sampling | 45 (100) | 98 (100) |
| Untreated at last follow up | 0 (0) | 39 (40) |
IGHV immunoglobulin variable heavy chain, FISH fluorescence in situ hybridization, nda no data available.